Die wachsende klinische Bedeutung der Radiofrequenz induzierten Ablation an der Leber wird begleitet von einer schnell zunehmenden Zahl an Publikationen. Im experimentellen Bereich liegt ein besonderes Augenmerk darauf Faktoren zu definieren, die die Variabilität der Nekroseausdehnung reduzieren. Das Pringle-Manöver steht hier für den Chirurgen an erster Stelle. Die Lokalrezidivrate steigt in großen Einzelserien und einer Metaanalyse bei einem Tumordurchmesser > 3 cm drastisch an. Ein offen chirurgischer Zugang ist mit einer signifikant geringeren Lokalrezidivrate nach RFA verbunden. Gallenwegsschäden und intrahepatische Abszesse sind die häufigsten Komplikationen. Die intraduktale Gallenwegskühlung vermindert experimentell und klinisch die Häufigkeit dieser Komplikationen. Die Indikation zur RFA ist bei hepatozellulären Karzinomen durch 3 prospektive, randomisierte Studien gesichert. Für die Indikation bei kolorektalen Metastasen liegen Einzelserien bei Patienten mit multiplen Metastasen und einem 3-Jahres-Überleben > 35 % vor. In zukünftigen multimodalen Therapiekonzepten wird die RFA aufgrund der günstigen Kosten / Nutzen-Relation einen im Detail noch zu definierenden Platz einnehmen.
Abstract
The growing clinical impact of radiofrequency ablation of liver lesions is reflected by a rapidly increasing number of published papers. Experimental work focuses on factors that reduce the variability of the ablation zone. The Pringle-maneuver plays a key role in this question from a surgeon's perspective. Large single center studies and a meta-analysis show a sharp rise in the rate of local recurrences for tumors larger 3 cm. An open surgical approach is significantly correlated to a low local recurrence rate. Bile duct lesions and intrahepatic abscesses are the most frequent complications. Intraductal bile duct cooling can prevent these complications. Three prospective randomized trials support the use of RFA for small hepatocellular carcinoma. The use of RFA in patients with multiple colorectal metastases is supported by single center studies showing a 3 year survival of > 35 %. The favourable cost / benefit ratio will make RFA a part of future multimodal cancer therapy concepts.
1
Abdalla E K, Vauthey J N, Ellis L M, Ellis V, Pollock R, Broglio K R, Hess K, Curley S A.
Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection / ablation for colorectal liver metastases.
Ann Surg.
2004;
239
818-825
2
Ahmed M, Liu Z, Afzal K S, Weeks D, Lobo S M, Kruskal J B, Lenkinski R E, Goldberg S N.
Radiofrequency ablation: effect of surrounding tissue composition on coagulation necrosis in a canine tumor model.
Radiology.
2004;
230
761-767
3
Bangard C, Gossmann A, Kasper H U, Hellmich M, Fischer J H, Holscher A H, Lackner K, Stippel D L.
Experimental radiofrequency ablation near the portal and the hepatic veins in pigs: differences in efficacy of a monopolar ablation system.
J Surg Res.
2006;
(im Druck)
4
Berber E, Pelley R, Siperstein A E.
Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study.
J Clin Oncol.
2005;
23
1358-1364
5
Cervone A, Sardi A, Conaway G L.
Intraoperative ultrasound (IOUS) is essential in the management of metastatic colorectal liver lesions.
Am Surg.
2000;
66
611-615
6
Chang C K, Hendy M P, Smith J M, Recht M H, Welling R E.
Radiofrequency ablation of the porcine liver with complete hepatic vascular occlusion.
Ann Surg Oncol.
2002;
9
594-598
8
Elias D, Sideris L, Pocard M, de Baere T, Dromain C, Lassau N, Lasser P.
Incidence of unsuspected and treatable metastatic disease associated with operable colorectal liver metastases discovered only at laparotomy (and not treated when performing percutaneous radiofrequency ablation).
Ann Surg Oncol.
2005;
12
298-302
9
Elias D, Sideris L, Pocard M, Dromain C, De Baere T.
Intraductal cooling of the main bile ducts during radiofrequency ablation prevents biliary stenosis.
J Am Coll Surg.
2004;
198
717-721
10
Fong Y, Fortner J, Sun R L, Brennan M F, Blumgart L H.
Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases.
Ann Surg.
1999;
230
309-318
11
Germer C T, Buhr H J, Isbert C.
Nonoperative ablation for liver metastases. Possibilities and limitations as a curative treatment.
Chirurg.
2005;
76
552-563
14
Goldberg S N.
Science to practice: can we differenziate residual untreated tumor from tissue responses to heat following thermal tumor ablation?.
Radiology.
2005;
234
317-318
15
Goldberg S N, Gazelle G S, Dawson S L, Rittman W J, Mueller P R, Rosenthal D I.
Tissue ablation with radiofrequency using multiprobe arrays.
Acad Radiol.
1995;
2
670-674
16
Goldberg S N, Gazelle G S, Dawson S L, Rittman W J, Mueller P R, Rosenthal D I.
Tissue ablation with radiofrequency: effect of probe size, gauge, duration, and temperature on lesion volume.
Acad Radiol.
1995;
2
399-404
17
Goldberg S N, Gazelle G S, Halpern E F, Rittman W J, Mueller P R, Rosenthal D I.
Radiofrequency tissue ablation: importance of local temperature along the electrode tip exposure in determining lesion shape and size.
Acad Radiol.
1996;
3
212-218
18
Goldberg S N, Grassi C J, Cardella J F, Charboneau J W, Dodd G D, Dupuy D E, Gervais D, Gillams A R, Kane R A, Lee F T, Livraghi T, McGahan J, Phillips D A, Rhim H, Silverman S G.
Image-guided tumor ablation: standardization of terminology and reporting criteria.
Radiology.
2005;
235
728-739
19
Hansen P D, Rogers S, Corless C L, Swanstrom L L, Siperstien A E.
Radiofrequency ablation lesions in a pig liver model.
J Surg Res.
1999;
87
114-121
20
Investigators C.
Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators.
Hepatology.
2000;
31
840-845
21
Jansen M C, van Hillegersberg R, Chamuleau R A, van Delden O M, Gouma D J, van Gulik T M.
Outcome of regional and local ablative therapies for hepatocellular carcinoma: a collective review.
Eur J Surg Oncol.
2005;
31
331-347
23
Kim S H, Lim H K, Choi D, Lee W J, Kim M J, Lee S J, Lim J H.
Changes in bile ducts after radiofrequency ablation of hepatocellular carcinoma: frequency and clinical significance.
AJR Am J Roentgenol.
2004;
183
1611-1617
24
Lencioni R A, Allgaier H P, Cioni D, Olschewski M, Deibert P, Crocetti L, Frings H, Laubenberger J, Zuber I, Blum H E, Bartolozzi C.
Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection.
Radiology.
2003;
228
235-240
25
Lin S M, Lin C J, Lin C C, Hsu C W, Chen Y C.
Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less.
Gut.
2005;
54
1151-1156
26
Lu D S, Yu N C, Raman S S, Limanond P, Lassman C, Murray K, Tong M J, Amado R G, Busuttil R W.
Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver.
Radiology.
2005;
234
954-960
27
Marchal F, Elias D, Rauch P, Zarnegar R, Leroux A, Stines J, Verhaeghe J L, Guillemin F, Carteaux J P, Villemot J P.
Prevention of biliary lesions that may occur during radiofrequency ablation of the liver: study on the pig.
Ann Surg.
2006;
243
82-88
29
Montgomery R S, Rahal A, Dodd G D, Leyendecker J R, Hubbard L G.
Radiofrequency ablation of hepatic tumors: variability of lesion size using a single ablation device.
AJR Am J Roentgenol.
2004;
182
657-661
30
Mulier S, Mulier P, Ni Y, Miao Y, Dupas B, Marchal G, De Wever I, Michel L.
Complications of radiofrequency coagulation of liver tumours.
Br J Surg.
2002;
89
1206-1222
31
Mulier S, Ni Y, Jamart J, Ruers T, Marchal G, Michel L.
Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors.
Ann Surg.
2005;
242
158-171
32
Mulier S, Ni Y, Miao Y, Rosiere A, Khoury A, Marchal G, Michel L.
Size and geometry of hepatic radiofrequency lesions.
Eur J Surg Oncol.
2003;
29
867-878
33
Ng K K, Lam C M, Poon R T, Shek T W, Fan S T, Wong J.
Delayed portal vein thrombosis after experimental radiofrequency ablation near the main portal vein.
Br J Surg.
2004;
91
632-639
34
Patterson E J, Scudamore C H, Owen D A, Nagy A G, Buczkowski A K.
Radiofrequency ablation of porcine liver in vivo: effects of blood flow and treatment time on lesion size.
Ann Surg.
1998;
227
559-565
35
Pawlik T M, Izzo F, Cohen D S, Morris J S, Curley S A.
Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients.
Ann Surg Oncol.
2003;
10
1059-1069
36
Pereira P L, Trubenbach J, Schenk M, Subke J, Kroeber S, Schaefer I, Remy C T, Schmidt D, Brieger J, Claussen C D.
Radiofrequency ablation: in vivo comparison of four commercially available devices in pig livers.
Radiology.
2004;
232
482-490
37
Pompili M, Mirante V G, Rondinara G, Fassati L R, Piscaglia F, Agnes S, Covino M, Ravaioli M, Fagiuoli S, Gasbarrini G, Rapaccini G L.
Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: Assessment of efficacy at explant analysis and of safety for tumor recurrence.
Liver Transpl.
2005;
11
1117-1126
38
Poon R T, Ng K K, Lam C M, Ai V, Yuen J, Fan S T, Wong J.
Learning curve for radiofrequency ablation of liver tumors: prospective analysis of initial 100 patients in a tertiary institution.
Ann Surg.
2004;
239
441-449
40
Santambrogio R, Podda M, Zuin M, Bertolini E, Bruno S, Cornalba G P, Costa M, Montorsi M.
Safety and efficacy of laparoscopic radiofrequency ablation of hepatocellular carcinoma in patients with liver cirrhosis.
Surg Endosc.
2003;
17
1826-1832
41
Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, Ishikawa T, Koike Y, Yoshida H, Kawabe T, Omata M.
A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma.
Gastroenterology.
2005;
129
122-130
42
Siperstein A, Garland A, Engle K, Rogers S, Berber E, String A, Foroutani A, Ryan T.
Laparoscopic radiofrequency ablation of primary and metastatic liver tumors. Technical considerations.
Surg Endosc.
2000;
14
400-405
43
Solazzo S A, Liu Z, Lobo S M, Ahmed M, Hines-Peralta A U, Lenkinski R E, Goldberg S N.
Radiofrequency ablation: importance of background tissue electrical conductivity - an agar phantom and computer modeling study.
Radiology.
2005;
236
495-502
44
Stippel D L, Bangard C, Kasper H U, Fischer J H, Holscher A H, Gossmann A.
Experimental bile duct protection by intraductal cooling during radiofrequency ablation.
Br J Surg.
2005;
92
849-855
45
Stippel D L, Brochhagen H G, Arenja M, Hunkemoller J, Holscher A H, Beckurts K T.
Variability of size and shape of necrosis induced by radiofrequency ablation in human livers: a volumetric evaluation.
Ann Surg Oncol.
2004;
11
420-425
46
Stippel D L, Tox U, Gossmann A, Beckurts K T, Holscher A H.
Successful treatment of radiofrequency-induced biliary lesions by interventional endoscopic retrograde cholangiography (ERC).
Surg Endosc.
2003;
17
1965-1970
47
Wiersinga W J, Jansen M C, Straatsburg I H, Davids P H, Klaase J M, Gouma D J, Van Gulik T M.
Lesion progression with time and the effect of vascular occlusion following radiofrequency ablation of the liver.
Br J Surg.
2003;
90
306-312
